Compare TRVI & TSLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRVI | TSLX |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 2019 | 2011 |
| Metric | TRVI | TSLX |
|---|---|---|
| Price | $13.60 | $17.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 9 |
| Target Price | $21.55 | ★ $21.61 |
| AVG Volume (30 Days) | ★ 982.4K | 704.7K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 10.82% |
| EPS Growth | ★ 31.91 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.41 | $16.96 |
| 52 Week High | $16.12 | $25.17 |
| Indicator | TRVI | TSLX |
|---|---|---|
| Relative Strength Index (RSI) | 45.75 | 42.62 |
| Support Level | $13.12 | $17.20 |
| Resistance Level | $14.57 | $18.65 |
| Average True Range (ATR) | 0.53 | 0.40 |
| MACD | -0.11 | 0.01 |
| Stochastic Oscillator | 23.23 | 21.12 |
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. The company partners with other companies across a variety of industries and provides creative solutions with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.